4410-16-6

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 9 carbon (C), 9 hydrogen (H), 1 bromine (Br), and 2 oxygen (O) atoms.

Explanation

The structure describes the arrangement of atoms in the molecule. It consists of a benzene ring with a bromine atom at the 1st position and a dioxolane group attached to the 4th position.
3. Brominated Organic Compound

Explanation

The presence of a bromine atom in the molecule classifies it as a brominated organic compound, which means it has a bromine atom covalently bonded to a carbon atom.
4. Benzene Ring

Explanation

The compound contains a benzene ring, which is a six-membered carbon ring with alternating single and double bonds between the carbon atoms.
5. Dioxolane Group

Explanation

The dioxolane group is a five-membered ring containing two oxygen atoms and three carbon atoms. In 1-BROMO-4-(1,3-DIOXOLAN-2-YLMETHYL)BENZENE, the dioxolane group is attached to the benzene ring through a methylene (-CH2-) bridge.

Explanation

The compound is used as a building block in the synthesis of various compounds, making it valuable in the fields of organic chemistry and pharmaceutical research.

Explanation

Due to its reactivity, 1-bromo-4-(1,3-dioxolan-2-ylmethyl)benzene can be used to create a wide range of specialty chemicals and pharmaceutical intermediates, which are essential for the development of new drugs and other chemical products.

Explanation

The compound is known for its reactivity, which allows it to participate in different chemical reactions to produce new compounds with different properties and applications.

Structure

1-Bromo-4-(1,3-dioxolan-2-ylmethyl)benzene

Applications

Organic synthesis and pharmaceutical research

Building Block

Synthesis of specialty chemicals and pharmaceutical intermediates

Reactivity

Capable of undergoing various chemical reactions

InChI:InChI=1/C10H11BrO2/c11-9-3-1-8(2-4-9)7-10-12-5-6-13-10/h1-4,10H,5-7H2

Upstream product

• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 107-21-1 ethylene glycol 
• 27200-79-9 p-bromophenylacetaldehyde 
• 4654-39-1 4-bromophenethanol 

Downstream Products

• 851034-23-6 2-(4-azidophenyl)acetaldehyde 

Relevant academic research and scientific papers

Combining neurobehavioral analysis and in vivo photoaffinity labeling to understand protein targets of methamphetamine in Casper zebrafish

Photoaffinity labeling (PAL) remains one of the most widely utilized methods of determining protein targets of drugs. Although useful, the scope of this technique has been limited to in vitro applications because of the inability of UV light to penetrate whole organisms. Herein, pigment-free Casper zebrafish were employed to allow in vivo PAL. A methamphetamine-related phenethylamine PAL probe, designated here as 2, demonstrated dose-dependent effects on behavior similar to methamphetamine and permitted concentration-dependent labeling of protein binding partners. Click chemistry was used to analyze binding partners via fluoroimaging. Conjugation to a biotin permitted streptavidin pull-down and proteomic analysis to define direct binding partners of the methamphetamine probe. Bioinformatic analysis revealed the probe was chiefly bound to proteins involved in phagocytosis and mitochondrial function. Future applications of this experimental paradigm combining examination of drug-protein binding interactions alongside neurobehavioral readouts via in vivo PAL will significantly enhance our understanding of drug targets, mechanism(s) of action, and toxicity/lethality.

Iodine-catalyzed tandem synthesis of terminal acetals and glycol mono esters from olefins

A new metal-free protocol is described for the synthesis of terminal acetals by tandem oxidative rearrangement of olefins using oxone as an oxidant in the presence of iodine. Moreover, a one-pot procedure for the preparation of glycol mono esters from olefins is also presented for the first time using the same reagent system. The Royal Society of Chemistry 2013.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.